Individualizing targets and tactics for high-risk patients with type 2 diabetes: practical lessons from ACCORD and other cardiovascular trials.
Diabetes Care., Oct;35(10):2100-7 (2012)
Basal insulin and cardiovascular and other outcomes in dysglycemia.
N. Engl. J. Med., Jul;367(4):319-28 (2012)
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
N. Engl. J. Med., Jul;367(4):309-18 (2012)
Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy.
Obstet Gynecol Int., 2012:649070 (2012)
Reevaluating goals of insulin therapy: perspectives from large clinical trials.
Endocrinol. Metab. Clin. North Am., Mar;41(1):41-56 (2012)
Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes: an analysis of baseline data from the ORIGIN trial.
Diabetes Care., Apr;35(4):749-53 (2012)
Twenty-four-hour profiles of plasma glucose, insulin, C-peptide and free fatty acid in subjects with varying degrees of glucose tolerance following short-term, medium-dose prednisone (20 mg/day) treatment: evidence for differing effects on insulin secreti
Clin. Endocrinol. (Oxf)., Aug;77(2):224-32 (2012)
International Forum for the Advancement of Diabetes Research and Care, April 29-30, 2011, Athens, Greece.
Diabetes Technol. Ther., Sep;13(9):967-79 (2011)
Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study.
Diabetes Obes Metab., Nov;13(11):1020-7 (2011)
Glycemic control and cardiovascular mortality.
Curr Opin Endocrinol Diabetes Obes., Apr;18(2):104-9 (2011)
Counterpoint: Intensive glucose control and mortality in ACCORD--still looking for clues.
Diabetes Care., Dec;33(12):2722-4 (2010)
More reasons to say goodbye to glyburide.
J. Clin. Endocrinol. Metab., Nov;95(11):4867-70 (2010)
Therapy: What evidence should guide the use of thiazolidinediones?
Nat Rev Endocrinol., Nov;6(11):600-2 (2010)
Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Circulation., Aug;122(8):844-6 (2010)
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial.
Diabetes Care., May;33(5):983-90 (2010)
Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy.
Arch. Ophthalmol., Mar;128(3):312-8 (2010)
Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor.
Diabetes Care., Feb;31 Suppl 2:S125-30 (2008)
Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention).
Am. Heart J., Jan;155(1):26-32, 32.e1-6 (2008)
Starting and advancing insulin for type 2 diabetes: algorithms and individualized methods are both necessary.
J. Clin. Endocrinol. Metab., Feb;93(2):372-4 (2008)
Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
Clin Ther., Aug;29(8):1607-19 (2007)